10-Q · August 3, 2026
AbbVie delivered strong Q2 top-line growth, with revenue of $16.990B rising 10.2% year over year and gross margin expanding to 75%, led by Skyrizi and Rinvoq. EPS of $3.65 recovered sharply from Q1 but missed the $3.77…
Earnings analysis · 10-Q
ABBV earnings analysis
Filed November 3, 2026 · Our reading of the company's report
The latest report
The supplied excerpt is limited to Part II and does not contain the income statement, balance sheet, cash-flow statement, segment data, MD&A, or risk-factor section needed to assess operating trends. It confirms…
Read full summary
The supplied excerpt is limited to Part II and does not contain the income statement, balance sheet, cash-flow statement, segment data, MD&A, or risk-factor section needed to assess operating trends. It confirms effective disclosure controls under Rule 13a-15(f), no material changes in internal control during the quarter, and 2,402 shares purchased outside the publicly announced repurchase program. Consequently, revenue, margins, EPS, cash flow, balance-sheet trends, segment performance, and quantitative guidance cannot be verified from the provided filing text.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
2,402 shares purchased
AbbVie reported 2,402 total shares purchased during the quarter, including 754 in July, 782 in August, and 866 in September, at an average price of $249.73 per share.
-
$1.83 billion buyback capacity remains
The company had approximately $1,831,437,567 remaining under its announced share-repurchase plans at September 30, 2026; the filing states that 0 of the 2,402 shares were purchased under those plans.
What to watch
-
Controls cannot eliminate all reporting risk
Management states that disclosure and internal controls provide only reasonable, not absolute, assurance and may be circumvented through error, collusion, or management override. The disclosure is made under Rule 13a-15(f); management nevertheless concluded the controls were effective as of the end of the quarter.
Management's outlook
The provided 10-Q excerpt does not include MD&A, financial statements, or a quantitative outlook. Guidance information is therefore not available from the supplied filing text.
Earlier filings 4
10-Q · May 8, 2026
AbbVie reported Q1 2026 revenues of $15.0 billion, a 12.4% increase year-over-year, with slightly lower diluted EPS at $2.65 compared to estimates of $2.66. Notably, the Immunology segment exhibited robust growth, with…
10-K · February 20, 2026
AbbVie describes itself as a single global, research-based biopharmaceutical company with leadership positions across immunology, neuroscience, oncology and aesthetics. The company delivered revenue growth in 2025 while…
10-Q · November 4, 2025
AbbVie reported Q3 2025 net revenues of $15,776 million, up $1,316 million (+9.1%) versus Q3 2024, but operating earnings fell to $1,904 million from $3,831 million a year ago and diluted EPS declined to $0.10 from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.